Fulgent Genetics (FLGT) Q4 2025 earnings review
Major Customer Defection Triggers a Massive 2026 Profitability Reversal
Fulgent delivered a solid Q4 to close out 2025 with 9% YoY revenue growth and positive Non-GAAP EPS. However, the forward outlook completely overshadowed the quarter. Management revealed their largest customer is moving a 'significant volume' of work in-house. While the company acquired Bako and StrataDx to patch the resulting revenue hole—guiding FY26 revenue to $350 million (+8%)—the bottom line is set to crater. FY26 guidance projects a Non-GAAP loss of ($1.45) per share, a violent reversal from FY25's $0.42 profit, raising serious questions about the underlying organic health of the core diagnostic business.
🐂 Bull Case
Despite losing significant volume from their top customer, Fulgent's $56M acquisition of Bako and StrataDx will keep total revenue growing (+8.5% YoY to $350M guided for FY26). The company has the balance sheet to buy its way through the transition.
The Phase 2 FID-007 (Head & Neck cancer) trial showed a 51% ORR and 7.8 months median PFS (vs 2.3 months standard of care). With $26M budgeted for therapeutic development in 2026, the pharma pivot is fully funded.
🐻 Bear Case
The loss of their top customer destroys operating leverage. Management is guiding from a $13.2M Non-GAAP profit in FY25 to a massive implied ~$45M Non-GAAP loss in FY26.
If FY26 revenue is guided to grow 8% to $350M, but relies heavily on the new Bako and StrataDx acquisitions to offset the customer defection, the core organic business is severely decelerating or actively contracting.
⚖️ Verdict: 🔴
Bearish. Management's claims of 'strong momentum' are directly contradicted by an impending collapse in 2026 earnings. Using acquisitions to mask organic customer defections is a red flag, and the transition from profitable diagnostic lab to cash-burning pharma company is accelerating.
Key Themes
The Narrative Contradiction: Momentum vs. Margin Collapse
Management touted that they 'drove margin improvements due to streamlined operations' in 2025. This narrative is sharply contradicted by the data. Non-GAAP Operating Margin compressed from -4.2% in 25Q3 to -10.7% in 25Q4. Furthermore, FY26 guidance projects a devastating Reversing trend to a ($1.45) Non-GAAP EPS loss. Operational efficiency cannot outrun the loss of your largest customer's volume.
Inorganic Rescue: Bako and StrataDx Acquisitions
To offset the lost revenue from their top customer, Fulgent executed the acquisitions of Bako and StrataDx for $56 million. Management expects these assets to partially or fully offset the revenue impact in the second half of 2026, serving as the primary bridge to their $350 million FY26 revenue target.
Macro Headwind: Government Shutdown Delays $106M Cash
The company ended the year with $705.5M in cash and investments, but notably excluded an expected $106.3M tax refund. Management specifically cited the Q4 2025 government shutdown as the macro catalyst for this delay, pushing the capital influx into 2026.
Therapeutic Pipeline Maturation
Fulgent is aggressively pivoting toward its Pharma segment. FID-007 (nanoencapsulated paclitaxel) has advanced through Phase 2, demonstrating an impressive 51% Objective Response Rate in heavily pre-treated Head & Neck cancer patients. Simultaneously, FID-022 is progressing through Phase 1 dose escalation. The company expects to spend $26M on therapeutics in 2026.
AI Integration in Digital Pathology
A key strategic driver remains the deployment of proprietary technology. Fulgent highlights that its laboratory services business is benefiting from active investments in AI and digital pathology solutions (such as the EZOPath image management system), aimed at increasing pathologist speed and long-term gross margin efficiency.
Sudden Legal Charge Hits the Books
Q4 GAAP results were crushed by a $14.5 million one-time 'professional liability expense.' Management added this back to reach their Non-GAAP figures, but an abrupt legal/liability charge of this magnitude requires strict monitoring for underlying quality or operational issues in the lab business.
Other KPIs
Decelerating sequentially. While up 9% YoY, revenue dipped slightly from $84.1M in Q3. This marks a stall in the momentum built during the first three quarters of the year, preceding the 2026 customer defection.
Down from $787.7 million at the end of Q3 2025. The company deployed capital toward its ongoing share repurchase program and the upcoming $56M M&A commitments. The balance remains highly supportive of their $26M expected pharma cash burn.
Reversing. Adjusted EBITDA went from a positive $0.7M in Q3 back to a loss of $4.5M in Q4. For the full year, the company generated an EBITDA loss of $9.4 million, worse than the $2.8 million loss in 2024.
Guidance
Decelerating. Implies roughly 8.5% YoY growth, down from 14% growth in FY25. Crucially, this includes an unspecified, but likely significant, inorganic contribution from the Bako and StrataDx acquisitions, meaning the core business is likely shrinking due to the largest customer leaving.
Reversing violently. The company printed $0.42 of positive Non-GAAP EPS in FY25. Plunging to a $1.45 loss highlights the massive deleveraging effect of losing high-margin volume from their top customer.
Assumes the receipt of the delayed $106M tax refund, $56M paid for Bako/StrataDx, $12M in CapEx, and $26M spent on the therapeutic business.
Key Questions
Sizing the Lost Customer
What exact percentage of 2025 revenue was tied to the largest customer that is now internalizing their volume, and what was the gross margin profile of that specific cohort?
Organic vs. Inorganic Growth
Of the $350 million revenue guidance for FY26, exactly how much is expected to be contributed by the new Bako and StrataDx acquisitions?
Path Back to Profitability
With Non-GAAP EPS swinging from +$0.42 to a guide of -$1.45 next year, what is the timeline and operational bridge required to return the diagnostic business to breakeven?
Professional Liability Details
Can you provide the underlying context for the $14.5 million professional liability expense recorded in Q4, and assure investors that the root cause has been remediated?